2m 2m 2m 2m 2m 2m 2m
- $27.3MMarket Cap
- 17.87%1-Year Change
- Medical Instruments & SuppliesIndustry
HARVARD BIO (HBIO)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 75
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Harvard Bioscience Tops Q2 Revenue Views
Harvard Bioscience reported Q2 2025 GAAP revenue of $20.5 million, exceeding analyst expectations by 9.3% despite an 11.3% year-over-year decline. The company showed improved operational cash flow and continued focus on new product development in biomedical research technologies.
08/11/2025, 7:12 AM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Key Executives
- John Duke
- Mark T. Frost
- David Sirois
- Lori Packer
- David Panzarella
Current Ownership Distribution
- Institutions500.6M (79.12%)
- Mutual Funds117.3M (18.53%)
- Insiders14.8M (2.34%)
- Other0 (0.00%)